Catalyst
Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in basal cell carcimonia set to begin in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
http://files.shareholder.com/downloads/REGN/4692963768x0x952295/5DCF481E-0BD3-485F-AE8E-2DBFB990BB60/REGN_News_2017_8_3_General_Releases.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Basal Cell Carcinoma, Pd-1, Phase 2
